{"id":12706,"date":"2021-08-29T02:17:10","date_gmt":"2021-08-29T02:17:10","guid":{"rendered":"http:\/\/www.16news.com.au\/?p=12706"},"modified":"2021-08-29T02:17:10","modified_gmt":"2021-08-29T02:17:10","slug":"breakthrough-pbs-listings-to-benefit-thousands-of-australians","status":"publish","type":"post","link":"http:\/\/www.16news.com.au\/index.php\/2021\/08\/29\/breakthrough-pbs-listings-to-benefit-thousands-of-australians\/","title":{"rendered":"Breakthrough PBS listings to benefit thousands of Australians"},"content":{"rendered":"

From 1 September 2021, thousands of Australians living with schizophrenia, liver disease, lymphoma and anaphylaxis will have access to new treatments through new and amended listings on the Pharmaceutical Benefits Scheme (PBS).
\nFor the first time, Australians with schizophrenia will have access to the antipsychotic Reagila\u00ae<\/sup>\u00a0(cariprazine).
\nSchizophrenia is a serious mental health condition with a wide range of symptoms and affects about 1 in 100 people.
\nThe exact cause of schizophrenia is unknown, and symptoms usually begin in late adolescence or early adulthood. Generally a long\u2011term illness, schizophrenia cause serious disability if left untreated.
\nIt is expect that over 39,500 Australians will benefit from this new treatment option. Without PBS subsidy, Australians might pay more than $1,200 per year for treatment.
\nIn another first, Ocaliva\u00ae<\/sup>\u00a0(obeticholic acid) is being listed from 1 September for the treatment of primary biliary cholangitis (PBC), a chronic disease which causes inflammation and scarring of the bile ducts within the liver.
\nWomen are 10 times more likely to develop PBC than men and while there is currently no cure, treatment can help slow the progression of the disease and ease symptoms.
\nIf left untreated and as liver damage worsens, primary biliary cholangitis can cause serious health problems, including liver cancer, liver scarring, high cholesterol and decreased mental function amongst other conditions.
\nWithout PBS subsidy, around 890 Australians per year might pay more than $60,500 per course of treatment.
\nAnapen\u00ae, an alternative brand of adrenaline auto-injector, will also be listed on the PBS for the first time for Australians with anaphylaxis, the most severe form of allergic reaction.
\nWhen injected, adrenaline works rapidly to reduce throat swelling, open up the airways and maintain heart function and blood pressure.
\nIn addition, Australians will also have access to a new strength of this medicine in the auto-injector form. Over 126,000 people would otherwise pay approximately $80 for this treatment without PBS subsidy
\nAustralians living with previously untreated CD30 positive peripheral T-cell lymphoma (PTCL) will also benefit from the extension of Adcetris\u00ae<\/sup>\u00a0(brentuximab vedotin) on the PBS.
\nLymphoma\u00a0is a cancer of the lymphatic system, which is part of the body’s germ-fighting network. PTCL is an aggressive cancer and affects both adults and children, however it is more common in those aged 60 years and over.
\nAround 65 Australians per year will benefit from this listing, which without PBS subsidy might pay more than $85,000 per course of treatment.
\nMinister for Health and Aged Care, Greg Hunt, said since 2013, the Coalition Government had approved more than 2,700 new or amended listings on the PBS.
\n\u201cThis represents an average of around 30 listings or amendments per month \u2013 or one each day \u2013 at an overall investment by the Government of $13.6 billion,\u201d Minister Hunt said.
\n\u201cWithout PBS subsidies many Australians would be thousands of dollars out of pocket, instead they\u2019ll only pay $41.30 per script or $6.60 with a concession card for these medicines.
\n\u201cThe Morrison Government\u2019s commitment to ensuring Australians can access affordable medicines, when they need them, remains rock solid.\u201d
\nThese PBS listings have been recommended by the independent Pharmaceutical Benefits Advisory Committee.<\/p>\n","protected":false},"excerpt":{"rendered":"

From 1 September 2021, thousands of Australians living with schizophrenia, liver disease, lymphoma and anaphylaxis will have access to new treatments through new and amended listings on the Pharmaceutical Benefits Scheme (PBS). For the first time, Australians with schizophrenia will have access to the antipsychotic Reagila\u00ae\u00a0(cariprazine). Schizophrenia is a serious mental health condition with a … Continue reading “Breakthrough PBS listings to benefit thousands of Australians”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-12706","post","type-post","status-publish","format-standard","hentry","category-aussie"],"_links":{"self":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/posts\/12706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=12706"}],"version-history":[{"count":0,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/posts\/12706\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=12706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=12706"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.16news.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=12706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}